
Brand Name | Status | Last Update |
|---|---|---|
| kit for the preparation of indium in 111 pentetreotide | ANDA | 2025-04-21 |
| octreoscan | New Drug Application | 2022-02-21 |
Code | Description |
|---|---|
| A9572 | Indium in-111 pentetreotide, diagnostic, per study dose, up to 6 millicuries |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 1 | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Pentetreotide |
| INN | pentetreotide |
| Description | Pentetreotide is a protein pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Protein |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108757 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | G083B71P98 (ChemIDplus, GSRS) |

